# TROPION-PanTumor02 (NCT05460273)

> A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

No report yet. It can be ordered.

- Drugs tested: datopotamab deruxtecan
- Indication: advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05460273
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Cancer
- Interventions: Datopotamab Deruxtecan (Dato-DXd)
- Enrollment: 119
- Primary outcome: Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)

## Indexed commentary on TROPION-PanTumor02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=tropion-pantumor02-nct05460273